Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Unity Biotechnology, Inc. (UBX)

5.51   0.42 (8.25%) 02-07 16:00
Open: 5.17 Pre. Close: 5.09
High: 5.719 Low: 5.17
Volume: 513,918 Market Cap: 78(M)

Technical analysis

as of: 2023-02-07 4:32:26 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6.67     One year: 7.8
Support: Support1: 3.9    Support2: 2.78
Resistance: Resistance1: 5.71    Resistance2: 6.67
Pivot: 4.58
Moving Average: MA(5): 5.03     MA(20): 4.39
MA(100): 3.38     MA(250): 6.12
MACD: MACD(12,26): 0.4     Signal(9): 0.4
Stochastic oscillator: %K(14,3): 88.9     %D(3): 87.3
RSI: RSI(14): 78.2
52-week: High: 18.5  Low: 0.58
Average Vol(K): 3-Month: 239 (K)  10-Days: 235 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ UBX ] has closed above the upper band by 11.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 31.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.72 - 5.74 5.74 - 5.76
Low: 5.12 - 5.14 5.14 - 5.16
Close: 5.47 - 5.5 5.5 - 5.54

Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Headline News

Wed, 08 Feb 2023
UBX, Etiqa partner to introduce 'insure now, pay later' scheme - The Manila Times

Wed, 08 Feb 2023
Music icon Ely Buendia collaborates with fine arts team - Manila Bulletin

Mon, 06 Feb 2023
Renkus-Heinz embarks on a passive drive - Worship AVL

Sat, 04 Feb 2023
UBIX.Network (UBX) has a Bullish Sentiment Score, is Rising, and Outperforming the Crypto Market Saturday: What's Next? - InvestorsObserver

Fri, 03 Feb 2023
'Self-harm and decay are not inevitable': This 45-year-old tech ... - Yahoo Finance

Tue, 31 Jan 2023
UBX Cloud commends Lawrence Tech. University student, Emilee ... - Digital Journal

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 58 (M)
% Held by Insiders 6.36e+006 (%)
% Held by Institutions 1.9 (%)
Shares Short 147 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.074e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 62.7
Return on Equity (ttm) -28.6
Qtrly Rev. Growth 5.02e+006
Gross Profit (p.s.) 0
Sales Per Share -151.15
EBITDA (p.s.) -4.54189e+007
Qtrly Earnings Growth -1.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -46 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 2.61

Stock Dividends

Dividend 0
Forward Dividend 112450
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.